Therapie des Antiphospholipid-Syndroms (APS) mit DOAKs

Hamostaseologie. 2019 Aug;39(3):298-300. doi: 10.1055/s-0039-1694789. Epub 2019 Aug 12.
[Article in German]
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Antibodies, Antiphospholipid / blood
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use*
  • Antiphospholipid Syndrome / blood
  • Antiphospholipid Syndrome / complications
  • Antiphospholipid Syndrome / drug therapy*
  • Factor Xa Inhibitors / administration & dosage
  • Factor Xa Inhibitors / therapeutic use*
  • Humans
  • Lupus Coagulation Inhibitor / blood
  • Meta-Analysis as Topic
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Rivaroxaban / administration & dosage
  • Rivaroxaban / therapeutic use*
  • Thromboembolism / etiology
  • Vitamin K / antagonists & inhibitors*
  • Warfarin / administration & dosage
  • Warfarin / therapeutic use*
  • beta 2-Glycoprotein I / blood

Substances

  • Antibodies, Antiphospholipid
  • Anticoagulants
  • Factor Xa Inhibitors
  • Lupus Coagulation Inhibitor
  • beta 2-Glycoprotein I
  • Vitamin K
  • Warfarin
  • Rivaroxaban